Folotyn for Non-Hodgkin's Lymphoma Islip NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

VIJAY SHAH, MD
(718) 204-0414
444 W Main Street
Patchogue, NY
LORI ATTIVISSIMO, MD
(516) 832-7100
99 Sunnyside Boulevard
Woodbury, NY
Rutheelu Bayer, MD
516-922-7818
26 Glendale Dr
Oyster Bay, NY
Bong Soon Kim, MD
631-344-7705
15th Fl Rm 040,
Stony Brook, NY
Anjali Sharma, MD
732-915-7789
208A Beaumont Pl
Coram, NY
JEFFREY VACIRCA, MD
(631) 751-3000
235 N Belle Mead Road
East Setauket, NY
BRUCE KAPPEL, MD
(516) 921-5533
40 Crossways Park Drive
Woodbury, NY
Patricia Burns, MD
631-751-8305
2500 Nesconset Hwy Ste 90
Stony Brook, NY
Alvin Stein, MD
516-796-1500
3601 Hempstead Tpke Ste 421
Levittown, NY
Hasan A Rizvi, MD
516-666-0262
180 E Main St
Bay Shore, NY
Data Provided by:
  

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Green Tea and Hematologic Malignancies Islip NY
Read more about Green Tea May Lower the Risk of Hematologic Malignancies.
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Islip NY